Skip to main content
×
×
Home

Striatal dopamine synthesis capacity in twins discordant for schizophrenia

  • P. Shotbolt (a1), P. R. Stokes (a1), S. F. Owens (a2), T. Toulopoulou (a2), M. M. Picchioni (a2) (a3), S. K. Bose (a1), R. M. Murray (a2) and O. D. Howes (a1) (a2)...
Abstract
Background

Elevated striatal dopamine synthesis capacity is thought to be fundamental to the pathophysiology of schizophrenia and has also been reported in people at risk of psychosis. It is therefore unclear if striatal hyperdopaminergia is a vulnerability marker for schizophrenia, or a state feature related to the psychosis itself. Relatives of patients with schizophrenia are themselves at increased risk of developing the condition. In this study we examined striatal dopamine synthesis capacity in both members of twin pairs discordant for schizophrenia.

Method

In vivo striatal dopamine synthesis capacity was examined using fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) scans in seven twin pairs discordant for schizophrenia and in a control sample of 10 healthy control twin pairs.

Results

Striatal 18F-DOPA uptake was not elevated in the unaffected co-twins of patients with schizophrenia (p=0.65) or indeed in the twins with schizophrenia (p=0.89) compared to the control group. Levels of psychotic symptoms were low in the patients with schizophrenia who were in general stable [mean (s.d.) Positive and Negative Syndrome Scale (PANSS) total=56.8 (25.5)] whereas the unaffected co-twins were largely asymptomatic.

Conclusions

Striatal dopamine synthesis capacity is not elevated in symptom-free individuals at genetic risk of schizophrenia, or in well-treated stable patients with chronic schizophrenia. These findings suggest that striatal hyperdopaminergia is not a vulnerability marker for schizophrenia.

Copyright
Corresponding author
*Address for correspondence: Dr P. Shotbolt, Clinical Imaging Centre, Imperial College London, Du Cane Road, London W12 0NN, UK. (Email: p.shotbolt@imperial.ac.uk)
References
Hide All
Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ (2004). Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biological Psychiatry 55, 10011006.
Belmaker R, Pollin W, Wyatt RJ, Cohen S (1974). A follow-up of monozygotic twins discordant for schizophrenia. Archives of General Psychiatry 30, 219222.
Bhatt MH, Snow BJ, Martin WR, Pate BD, Ruth TJ, Calne DB (1991). Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Annals of Neurology 29, 673677.
Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, Grasby PM (2008). Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophrenia Research 106, 148155.
Cannon TD, Kaprio J, Lonnqvist J, Huttunen M, Koskenvuo M (1998). The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Archives of General Psychiatry 55, 6774.
Cardno AG, Gottesman II (2000). Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. American Journal of Medical Genetics 97, 1217.
Cordes M, Snow BJ, Cooper S, Schulzer M, Pate BD, Ruth TJ, Calne DB (1994). Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren. Annals of Neurology 36, 667670.
Dagher A, Gunn R, Lockwood G, Cunningham VJ, Grasby PM, Brooks DJ (1998). Measuring neurotransmitter release with PET: methodological issues. In Quantitative Functional Brain Imaging with Positron Emission Tomography(ed. Carson R., Daube-Witherspoon and M.Herscovitch P.), pp. 449454. Academic Press: San Diego.
Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL (1997). Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research 23, 167174.
Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Moeller JR, Patlak CS, Fahn S (1993). Striatal 18F-dopa uptake: absence of an aging effect. Journal of Cerebral Blood Flow and Metabolism 13, 881888.
Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ (2000). 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Research 100, 111.
Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, Bartenstein P, Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P (2003). Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28, 787794.
Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS (2003). Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Human Brain Mapping 19, 224247.
Hardin JW, Hibe JM (2003). Generalized Estimating Equations. Chapman & Hall/CRC: Boca Raton, FL.
Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Hietala J, Cannon TD (2005). Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Archives of General Psychiatry 62, 371378.
Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P (2011). Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Molecular Psychiatry. Published online: 1 March 2011. doi:10.1038/mp.2011.20.
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S (2009 a). Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Current Pharmacological Design 15, 25502559.
Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophrenia Bulletin 35, 549562.
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009 b). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry 66, 1320.
Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, Solin O, Ilonen T, Korkeila J, Ristkari T, McGlashan T, Salokangas RK, Hietala J (2008). Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biological Psychiatry 63, 114117.
Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D (1996). Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. Journal of Nuclear Medicine 37, 17601765.
Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, Okumura M, Otsuka T, Suhara T (2009). Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? Journal of Neurosciences 29, 1373013734.
Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.
Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry 46, 5672.
Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G (2004). A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. American Journal of Psychiatry 161, 818825.
Martin WR, Palmer MR, Patlak CS, Calne DB (1989). Nigrostriatal function in humans studied with positron emission tomography. Annals of Neurology 26, 535542.
Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. Journal of Cerebral Blood Flow and Metabolism 23, 285300.
McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004). Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Archives of General Psychiatry 61, 134142.
Navari S, Dazzan P (2009). Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 39, 17631777.
Patlak CS, Blasberg RG, Fenstermacher JD (1983). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Journal of Cerebral Blood Flow and Metabolism 3, 17.
Rabe-Hesketh S, Skrondal A (2010). Multilevel and Longitudinal Modeling using Stata. Stata Press: College Station, TX.
Rousset OG, Ma Y, Evans AC (1998). Correction for partial volume effects in PET: principle and validation. Journal of Nuclear Medicine 39, 904911.
Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS (1990). Striatal function in normal aging: implications for Parkinson's disease. Annals of Neurology 28, 799804.
Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rossler A, Borgwardt SJ (2009). The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia? – a systematic review. Current Pharmacological Design 15, 25352549.
Spitzer RL, Williams JB, Gibbon M, First MB (1992). The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Archives of General Psychiatry 49, 624629.
Studholme C, Hill DL, Hawkes DJ (1997). Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Medical Physics 24, 2535.
Sullivan PF, Kendler KS, Neale MC (2003). Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of General Psychiatry 60, 11871192.
Turkheimer FE, Aston JA, Asselin MC, Hinz R (2006). Multi-resolution Bayesian regression in PET dynamic studies using wavelets. NeuroImage 32, 111121.
Turkheimer FE, Brett M, Visvikis D, Cunningham VJ (1999). Multiresolution analysis of emission tomography images in the wavelet domain. Journal of Cerebral Blood Flow and Metabolism 19, 11891208.
Williams RL (2000). A note on robust variance estimation for cluster-correlated data. Biometrics 56, 645646.
Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663667.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 9
Total number of PDF views: 45 *
Loading metrics...

Abstract views

Total abstract views: 231 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd January 2018. This data will be updated every 24 hours.